908 Devices Inc. Reports Strong Q1 2025 Growth

908 Devices Inc. ( (MASS) ) has released its Q1 earnings. Here is a breakdown of the information 908 Devices Inc. presented to its investors.

908 Devices Inc., a small-cap growth company, specializes in handheld chemical analysis tools for critical health, safety, and defense applications. The company reported a strong start to 2025 with a 59% increase in first-quarter revenue, driven by significant growth in product and service sales. The company highlighted the divestiture of its bioprocessing product portfolio and a notable order from the Texas Department of Public Safety.

The first quarter saw total revenue of $11.8 million, with handheld product and service revenue growing by 86% year-over-year. Recurring revenue also increased by 54%, making up 37% of total revenues. Despite a net loss from continuing operations, the company achieved a net income of $43.6 million due to gains from the divestiture of its bioprocessing portfolio.

Operating expenses rose to $16.6 million, influenced by non-cash charges and expenses from the RedWave Technology acquisition. The company’s adjusted EBITDA showed a reduced loss compared to the previous year, indicating improved financial management. The installed base of devices grew by 28%, reflecting strong market demand.

Looking ahead, 908 Devices maintains its revenue outlook for 2025, expecting growth between 11% and 15% compared to 2024. The company remains focused on achieving adjusted EBITDA profitability by the fourth quarter and expanding its leadership in chemical detection technology.